Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q60681801)
Watch
English
Alemtuzumab for multiple sclerosis: who and when to treat?
scientific article published in The Lancet
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
title
Alemtuzumab for multiple sclerosis: who and when to treat?
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
main subject
multiple sclerosis
1 reference
based on heuristic
inferred from title
author
Till Sprenger
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
author name string
Ludwig Kappos
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
language of work or name
English
0 references
publication date
2 November 2012
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
volume
380
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
issue
9856
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
page(s)
1795-1797
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
cites work
Oral treatment for multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple sclerosis: new insights in pathogenesis and novel therapeutics.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
CAMPATH-1H in multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predicting risk of progressive multifocal leukoencephalopathy from natalizumab
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961859-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(12)61859-5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
PubMed publication ID
23128041
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23128041
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23128041%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit